Non-small Cell Lung Cancer
11
Companies
14
Drug Programs
1
Phase 3
0
Upcoming PDUFAs
Regeneron Pharmaceuticals, Inc.
Libtayo
BioNTech SE
BNT327
MERCK
Arm A: Pemetrexed Cisplatin
Sanofi
oxaliplatine / gemcitabine / Vinorelbine
Roche Holding AG
erlotinib HCl
Gritstone bio, Inc.
GRT-C901
Gritstone bio, Inc.
GRT-C903
Black Diamond Therapeutics, Inc.
silevertinib (BDTX-1535) monotherapy
Revolution Medicines, Inc.
RMC-4630
Geron Corporation
Bevacizumab
BRISTOL MYERS SQUIBB CO
Vinorelbine (Navelbine)
MERCK
Pemetrexed Cisplatin
Mirati Therapeutics, Inc.
MGCD265
Sanofi
oxaliplatine/gemcitabine/Vinorelbine
| Company | Drug | Phase | Designations | Timeline | Trial ID |
|---|---|---|---|---|---|
| REGN Regeneron Pharmaceuticals, Inc. | Libtayo | Phase 3 | FT | — | — |
| BNTX BioNTech SE | BNT327 | Phase 2 | — | — | — |
| MRK MERCK | Arm A: Pemetrexed Cisplatin | Phase 2 | — | — | — |
| SNY Sanofi | oxaliplatine / gemcitabine / Vinorelbine | Phase 2 | — | — | — |
| RHHBY Roche Holding AG | erlotinib HCl | Phase 2 | — | — | — |
| GRTS Gritstone bio, Inc. | GRT-C901 | Phase 2 | — | — | — |
| GRTS Gritstone bio, Inc. | GRT-C903 | Phase 2 | — | — | — |
| BDTX Black Diamond Therapeutics, Inc. | silevertinib (BDTX-1535) monotherapy | Phase 2 | — | — | — |
| RVMD Revolution Medicines, Inc. | RMC-4630 | Phase 2 | — | — | — |
| GERN Geron Corporation | Bevacizumab | Phase 2 | — | — | — |
| CELG-RI BRISTOL MYERS SQUIBB CO | Vinorelbine (Navelbine) | Phase 2 | — | — | — |
| MRK MERCK | Pemetrexed Cisplatin | Phase 2 | — | — | — |
| MRTX Mirati Therapeutics, Inc. | MGCD265 | Phase 2 | — | — | — |
| SNY Sanofi | oxaliplatine/gemcitabine/Vinorelbine | Phase 2 | — | — | — |
Not financial advice
Signals are probabilistic and based on historical data — past performance doesn't guarantee future results. Do your own research.